A Revolutionary Breakthrough in Biomedical Testing: AmeboGenesis Introduces Sustainable Amebocyte Production for LAL Testing to Detect Bacterial Contamination

March 26, 2024 7:15 AM

Limulus Amebocyte Lysate (LAL) Can Now Be Produced Without Harvesting the Blood of ~800,000 Horseshoe Crabs Each Year, Which Will Help Restore Their Natural PopulationGERMANTOWN, MD / ACCESSWIRE / March 26, 2024 / AmeboGenesis™ has achieved a significant milestone with the introduction of a sustainable Amebocyte production process. This innovative technology produces bio-identical Amebocytes necessary for the production of LAL for medical...

Read more

Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call

March 25, 2024 5:00 PM

Call Scheduled for Monday, April 1st, 2024, at 4:30 pm ETNEW YORK, NY / ACCESSWIRE / March 25, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, announced that the Company plans to hold its first investor earnings call to discuss the results contained in its FY 2023 Form 10K, which it plans to file that day, and its outlook for FY 2024.The Company plans to hold its earnings call, open to the public, at 4:30 pm ET...

Read more

Faro Health Inc. Appoints Patrick Leung as Chief Technology Officer

March 25, 2024 9:00 AM

SAN DIEGO, CA / ACCESSWIRE / March 25, 2024 / Faro Health Inc., the emerging leader in clinical trial development using AI to optimize protocol design and outcomes, is pleased to announce the appointment of Patrick Leung as Chief Technology Officer.This appointment comes at a time of significant momentum for Faro Health as it continues to evolve its AI-based platform for optimal clinical trial design and document generation. Patrick is a native...

Read more

MRES: M2Bio Food and Beverage Wraps Up 2023/ 2024 Looking Ahead

March 22, 2024 10:15 AM

CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / March 22, 2024 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specialising in alternative plant-based cannabinoids, medical psilocybin, and cutting-edge mental health therapeutic research driven by artificial intelligence (AI), is pleased to announce the following updates with its M2Bio Food and Beverage division:M2Bio Sciences...

Read more

Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results

March 22, 2024 8:00 AM

Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumorsEnded the year with $9.0 million of cash to fund operationsFRAMINGHAM, MA / ACCESSWIRE / March 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies...

Read more

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference

March 21, 2024 4:30 PM

TORONTO, ON / ACCESSWIRE / March 21, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that the company will participate in a Fireside Chat and host one-on-one meetings at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on March 28, 2024.The Fireside Chat discussion between Edesa's Chief...

Read more

Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results

March 21, 2024 4:05 PM

- Initiated enrollment of DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial in Q4 2023 -- Raised $9.1 million in gross proceeds from three financings completed in 2023 -- Received issuance of Japanese patent for DMT410 for the treatment of hyperhidrosis -SAN DIEGO, CA / ACCESSWIRE / March 21, 2024 ./ Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company...

Read more

Public Health Vaccines Announces Initiation of First Clinical Trial Evaluating Its Marburg Virus Vaccine

March 21, 2024 8:00 AM

CAMBRIDGE, MA / ACCESSWIRE / March 21, 2024 / Public Health Vaccines, LLC (PHV), a biotechnology company out of Cambridge, Massachusetts, developing novel products against emerging infectious diseases, has started its Phase 1 clinical trial (NCT06265012) to evaluate the safety and immunogenicity of the company's single-dose vaccine (PHV01) against Marburg virus - a hemorrhagic fever virus of the Filoviridae family that causes Marburg virus...

Read more

AppYea Launches E-Commerce Store on Amazon Broadening Distribution

March 20, 2024 11:45 AM

AppySleep smart wristband now available on AmazonSuccessful fulfillment of all pre-ordersEntering the 17.9 Billion Sleep Tech Device MarketGAN YAVNE, ISRAEL / ACCESSWIRE / March 20, 2024 / AppYea, Inc. (OTCQB:APYP), developer of an innovative and accurate wearable monitoring solution to treat sleep apnea and snoring, today announced the launch of its new e-commerce store on Amazon. AppYea recently commenced its commercial phase, with the first...

Read more

Minutes from Annual General Meeting in FluoGuide A/S

March 20, 2024 9:45 AM

COPENHAGEN, DENMARK / ACCESSWIRE / March 20, 2024 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company") held its annual general meeting on 20 March 2024.To the shareholders of FluoGuide A/SThe Annual General Meeting was held Wednesday 20 March 2024 at 09:00 AM (CET) at the Company's premises, Ole Maaløes Vej 3, room M0.08 - Oxygen, DK-2200 Copenhagen N, Denmark.Notice: Represented at the annual general meeting was share capital of nominal...

Read more

CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration

March 20, 2024 8:30 AM

SINGAPORE / ACCESSWIRE / March 20, 2024 / CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "the Company"), a Singapore biopharmaceutical company that focuses on utilizing its licensed proprietary technologies to create novel allogeneic cell-based immunotherapies for treating a range of cancers, recently announced that it has entered into a research collaboration agreement with Sengkang General Hospital Pte Ltd., a public hospital in...

Read more

AbTherx Appoints Jessica Stark, PhD, as Scientific Advisor

March 20, 2024 6:00 AM

Glycoimmunology expert and co-inventor of AbLec technology joins AbTherx to expand expertise around challenging drug targetsMOUNTAIN VIEW, CA / ACCESSWIRE / March 20, 2024 / AbTherx, Inc., a biotechnology company with innovative technologies that enable and accelerate antibody discovery, today announced the appointment of Jessica Stark, PhD, as a scientific advisor. In her new role, Dr. Stark will provide guidance on the company's research...

Read more

SingleTimeMicroneedles, CEO Jasdeep Singh, Wins 2024 SXSW Pitch Competition

March 19, 2024 9:00 AM

SingleTimeMicroneedles wins the Food, Nutrition, and Health Category.STORRS, CT / ACCESSWIRE / March 19, 2024 / SingleTimeMicroneedles, Inc., a microneedle drug development and delivery company, was selected as the winner of the Food, Nutrition, and Health category for the 15th annual SXSW Pitch (formerly SXSW Accelerator). SingleTimeMicroneedles STM and Jasdeep Singh In a field of winners dominated by artificial intelligence companies, STM...

Read more

Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider

March 19, 2024 9:00 AM

Petros begins enrollment in AI integrated Human Factors Study to optimize self-screening, continuing its efforts to make STENDRA (avanafil) the first erectile dysfunction medication to achieve OTC Status(Please see important safety information below)NEW YORK, NY / ACCESSWIRE / March 19, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development...

Read more

Nascent Collaborates With Hypospray Pharma on Proprietary Transdermal Delivery System

March 19, 2024 8:00 AM

NORTH PALM BEACH, FL / ACCESSWIRE / March 19, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies targeting various cancer types, and HypoSpray Pharma ("HypoSpray®"), a clinical and commercial stage drug delivery technology company, announced today a collaboration to develop an alternative delivery mechanism for patients who can...

Read more

CB Scientific, Inc. Concludes its Annual Meeting of Stockholders

March 19, 2024 7:00 AM

Shareholders endorse name change to Cardiac Biotech Solutions, Inc. subject to regulatory approvalLAS VEGAS, NV / ACCESSWIRE / March 19, 2024 / CB Scientific, Inc. (OTCQB:CBSC) ("CBSC" or the "Company"), a designer, manufacturer and distributor of non-invasive ambulatory cardiac monitoring products and services, announced today that the company successfully concluded its Annual Meeting of Stockholders ("Annual Meeting") on Thursday, March 14,...

Read more

Canopus Biopharma Inc. (CBIA) dba Blue Heaven Coffee Inc. (BHC) Announces and Secures New Unattended Retail Management Platform - Parlevel systems (VMS)

March 19, 2024 7:00 AM

LAS VEGAS, NV / ACCESSWIRE / March 19, 2024 / Canopus Biopharma Inc. (OTC PINK:CBIA) dba Blue Heaven Coffee Inc. (BHC) has partnered with Parlevel Systems to assist with the optimization of its vending, micro market, and unattended retail operations.Parlevel, recognized as the fastest-growing provider of vending management systems (VMS) for vending operators and office coffee service (OCS) providers, offers innovative solutions tailored to...

Read more

Deverra Therapeutics Granted FDA Regenerative Medicine Advanced Therapy and Orphan Drug Designations for DVX101 (Dilanubicel) for the Treatment of Acute Myeloid Leukemia

March 19, 2024 6:00 AM

Designations Validate Preliminary Data and Enhances Ability to Offer Dilanubicel to Cancer PatientsSEATTLE, WA / ACCESSWIRE / March 19, 2024 / Deverra Therapeutics Inc., a clinical-stage biotechnology company developing allogeneic universal donor cell therapy treatments to fight cancer and other life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy...

Read more

Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis

March 19, 2024 3:20 AM

STOCKHOLM, SE / ACCESSWIRE / March 19, 2024 / Vicore Pharma Holding (STO:VICO)AlmeeTM is the first digital therapy to address anxiety and quality of life in patients living with pulmonary fibrosis (PF).AlmeeTM has shown effectiveness in reducing anxiety symptoms and improving health-related quality of life in the COMPANION study as reported earlier this year, driving a 2.7-point increase in GAD-7 score and a 4.4 improvement in KBILD...

Read more

Biovica rReceives Positive Patent Notification for Immunotherapies

March 19, 2024 3:20 AM

UPPSALA, SE / ACCESSWIRE / March 19, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in blood-based cancer monitoring, has received a positive International Preliminary Report on Patentability (IPRP) covering the use of TKa as a prognostic and monitoring marker in cancer treatment outside the CDK 4/6 inhibitor space, expanding the market potential for the DiviTum TKa technology by four to six times."This is a...

Read more